
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a steady increase in its EsoGuard test processing, moving from 2,756 tests in Q2 to 2,841 in Q3, highlighting the growing demand for its diagnostic offerings. The company’s current valuation is seen as attractive, particularly given its anticipated growth trajectory in 2025 and 2026 for its product lines, which include EsoGuard and esocheck. Additionally, the positive sentiment around the company's pipeline of products aligns with the assessment that it offers substantial upside potential relative to its inherent risks.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), falling short of both internal and consensus estimates, highlighting ongoing financial struggles. Additionally, there has been a consistent decline in the number of EsoGuard tests processed, with Q2 figures showing a decrease to 2,756 tests from 3,034 tests in Q1, indicating potential issues with demand and market traction. The company's early-stage commercialization status for its Lucid business and the Veris platform, coupled with significant risks related to balance sheet liquidity, regulatory approvals, and market competition, contribute to a fundamentally negative outlook for its stock.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares